these compounds, develop them at very, very early stages, and then license them out, let somebody else take on all the risk. And then they just sit back and collect the money. And so I really like that model because it's not so boom and bust like it is for some biotechs. You saw Moderna did nothing for years. I mean, they couldn't get anything across the goal line. And then suddenly, COVID happened and they're one of the biggest names in biotech. So it's nice not to just be staring at your computer screen on the day that you know that an FDA approval is coming out, just blue, just hoping that something positive happens because you know the stock could move 50% either up or down, depending on the news. So those are the kinds of things I'm looking at these days. Frank Curzio Yeah, the volatility in that you can look any day, I mean, go to Finviz free sites, and you'll see the winners and losers smoke at you'll always see those like crazy. They just they're on the losers list that the (25/35)